Hi, I'm Luciano Costa, myeloma physician at University of Alabama at Birmingham. I'm here at the International Myeloma Society meeting in my home country of Brazil in Rio de Janeiro. And I'm having the joy to present an oral abstract on a combination of mesignomide, which is a new cell mod, a cerebral modulator oral drug. You can think of that as being the successor of immunomodulatory agents. And those drugs have a very powerful anti-myeloma effect and on themselves or in combination with dexamethasone are able to lead to response in almost half the patients as previously demonstrated in other clinical trials. The study that we are presenting has to do with understanding how cells become resistant to immunomodulatory agents and cell mods. And that is through upregulation of several different pathways, including one pathway that's called the EZH2, which is a prescription factor modifier. This is kind of a new frontier in myeloma, but that target is very relevant in other cancers to the point that we have a drug that is approving other malignancies called tazametrostat that is an EZH inhibitor. And we know that is a relevant pathway and a synergistic pathway with the cerebrone downward cascade that we have in myeloma. So this cohort that I'm presenting combined with the metastat, mizidomide, and dexamethasone in patients with relapsed refractory myeloma. So it's only 15 patients, but it's one of probably the most heavily pretreated cohorts we have in any myeloma study, with all patients being triple class exposed, many most triple class refractory, and a substantial number of patients having received prior T-cell redirective therapy, including CAR T-cells, including patients with multiple CAR T-cells and T-cell redirecting therapy. And despite that, we saw a very encouraging safety profile. Doesn't seem to be any more toxic than mizidomide and dexamethasone alone, which is mostly transient, low white blood cell count or low platelets that get addressed by delaying the dose or reducing the dose. Very little, relatively speaking, in terms of infection. No other unusual, unexpected toxicity. And most importantly, you work on the majority of the patients. In the recommended phase two trials, phase two dose, you work in near two-thirds of the patients. So this study is going forward with expansion of the highest cohort, as well as other cohorts of exploring other combinations of mizidomide with drugs that target other different pathways that we know are relevant for C-mead and CEL-mod-Rosizkis.
HealthTree • October 8, 2024